Undifferentiated Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Conditions: Metastatic Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Metastatic Nasopharyngeal Undifferentiated Carcinoma; Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Keratinizing Squa mous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8; Stage IVA Nasopharyngeal Carcinoma AJCC v8; Stage IVB Nasopharyngeal Carcinoma AJCC v8 Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Gemcitabine; Bi...
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Conditions: Leiomyosarcoma; Myxofibrosarcoma; Resectable Dedifferentiated Liposarcoma; Resectable Soft Tissue Sarcoma; Resectable Undifferentiated Pleomorphic Sarcoma; Soft Tissue Fibrosarcoma; Spindle Cell Sarcoma; Stage I Retroperitoneal Sarcoma American Joint Committee on Cancer (AJCC) v8; Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IA Retroperitoneal Sarcoma AJCC v8; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IB Retroperitoneal Sarcoma AJCC v8; Stage IB Soft Tissue Sarcoma of the Tru nk and Extremities...
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials